Jie Wu1,#, Guiwen Liang1,#, Ya Pan1,#, Talaibaike Maimaijuma2,3, Xianggui Xu2,3, Juying Lu1, Zhongwei Huang1,*, Lei Qi1,*, Haiyan Jiang1,*
Structural and Congenital Heart Disease, Vol.21, No.2, 2026, DOI:10.32604/schd.2026.077080
- 11 June 2026
Abstract Background: Children with congenital heart disease (CHD) complicated by severe infection often present with immature immune function and poor prognosis. Evidence supporting the use of glucocorticoids in this population, particularly with dynamic immune monitoring, remains limited. Methods: A retrospective analysis was conducted on 183 CHD children with severe infections admitted to the Pediatric Intensive Care Unit (PICU) from 2019 to 2023. Patients were divided into two groups: the glucocorticoid intervention group (n = 92, methylprednisolone + standard treatment) and the control group (n = 91, standard treatment). Immune indicators (Interleukins-6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT), CD4+/CD8+ ratio… More >